CTRI/2013/05/003683已完成4 期
Evaluation of the Effectiveness, Safety and Tolerability of Dhathri Fair Skin Cream in Imparting Skin Fairness, Reduction of Black Spots and Dark Circles Under Eyes in Human Adults
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy Male and female subjects aged between
- •18 and 35 years.
- •2. Subjects who can read, understand, give written informed consent form and who are willing to comply with the study protocol.
- •3. Subjects of skin grade III, IV, and V (Fitzpatrick Scale).
- •4. Subjects with any type of skin like oily, normal and dry.
- •5. Subjects having at least any one of the following: black spots, dark circles under eyes. (Minimum 5 subjects with black spots and Minimum 5 subjects with dark circles under eyes)
- •6. Subjects showing negative to sensitivity test.
- •7. Subject who has not participated in a similar investigation in the past four weeks.
- •8. Subjects having pigmentation freckles, pigmented demarcation lines, and uneven tone skin will also be included.
排除标准
- •1. Women who are pregnant or lactating.
- •2. A known history or present condition of allergic response to any cosmetic products.
- •3. Subjects with a history of Insomnia or sleeplessness.
- •4. Subject having skin diseases (e.g. moderate to severe acne vulgaris face, psoriasis, active atopic dermatitis, melasma, which will interfere with the test readings.
- •5. Subjects on oral medications (e.g. steroids, anti-oxidant) which will compromise the study.
- •6. Systemic treatment of the skin that may change the state of the skin, in the previous 30 days.
- •7. Subjects not willing to discontinue other fairness/whitening/ brightening creams including vitamin A derivatives.
- •8. Subjects showing allergic reactions to any component of the tested products.
- •9. Subjects who has a history of intense sun exposure.
- •10. Chronic illness which may influence the cutaneous state of the skin.
- •11. Subject participating in any other cosmetic or therapeutic trial.
研究者
相似试验
进行中(未招募)
1 期
Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain componentsevere chronic low back pain with a neuropathic pain componentMedDRA version: 12.1Level: LLTClassification code 10024891Term: Low back painMedDRA version: 12.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2010-019998-14-BEGrünenthal GmbH800
进行中(未招募)
不适用
Comparison of tapentadol PR and oxycodone/naloxone PREUCTR2012-002943-11-ITGrünenthal GmbH240
进行中(未招募)
不适用
Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain componentsevere chronic low back pain with a neuropathic pain componentMedDRA version: 12.1Level: LLTClassification code 10024891Term: Low back painMedDRA version: 12.1Level: LLTClassification code 10054095Term: Neuropathic painEUCTR2010-019998-14-NLGrünenthal GmbH800
进行中(未招募)
不适用
Comparison of increasing doses of tapentadol vs a combination of tapentadol and pregabaliSevere chronic low back pain with a neuropathic pain componentMedDRA version: 14.0Level: LLTClassification code 10054095Term: Neuropathic painSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 14.0Level: LLTClassification code 10024891Term: Low back painSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-019998-14-ATGrünenthal GmbH800
已完成
3 期
Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain componenternstig chronische lage rugpijn met een neuropatische componentneuropatic pain and low back painNL-OMON36404Grunenthal50
